The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Proof of mechanism (POM) in the first-in-human trial of two novel indenoisoquinoline, non-camptothecin topoisomerase I (TOP1) inhibitors.
James H. Doroshow
No relevant relationships to disclose
Jiuping Jay Ji
No relevant relationships to disclose
Alice Chen
No relevant relationships to disclose
Deborah Allen
No relevant relationships to disclose
Yiping Zhang
No relevant relationships to disclose
Scott M Lawrence
No relevant relationships to disclose
Thomas D. Pfister
No relevant relationships to disclose
Lihua Wang
No relevant relationships to disclose
Christophe E. Redon
No relevant relationships to disclose
William Bonner
No relevant relationships to disclose
Giovanna Speranza
No relevant relationships to disclose
Marcie K. Weil
No relevant relationships to disclose
Julie Eiseman
No relevant relationships to disclose
Julianne L. Holleran
No relevant relationships to disclose
Robert J. Kinders
No relevant relationships to disclose
Jan Hendrik Beumer
No relevant relationships to disclose
Ralph E. Parchment
No relevant relationships to disclose
Yves Pommier
No relevant relationships to disclose
Joseph E. Tomaszewski
No relevant relationships to disclose
Shivaani Kummar
No relevant relationships to disclose